


Vault Series: Counting Cards in Biotech
No EBITDA, no revenue, no product. What’s not to like? Despite being fraught with risk, investing in biotech stocks can be highly lucrative. Michael Caldwell, a portfolio manager at Driehaus Capital Management led a highly interactive discussion with a roomful of...